**Supplementary Table 1.** STARD 2015: An updated list of essential items for reporting diagnostic accuracy studies

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Section & Topic** | **No** | **Item** |
|  |  |  |  |
|  | **TITLE OR ABSTRACT** |  |  |
|  |  | **1** | Identification as a study of diagnostic accuracy using at least one measure of accuracy (such as sensitivity, specificity, predictive values, or AUC) |
|  | **ABSTRACT** |  |  |
|  |  | **2** | Structured summary of study design, methods, results, and conclusions (for specific guidance, see STARD for Abstracts) |
|  | **INTRODUCTION** |  |  |
|  |  | **3** | Scientific and clinical background, including the intended use and clinical role of the index test |
|  |  | **4** | Study objectives and hypotheses |
|  | **METHODS** |  |  |
|  | *Study design* | **5** | Whether data collection was planned before the index test and reference standard were performed (prospective study) or after (retrospective study) |
|  | *Participants* | **6** | Eligibility criteria  |
|  |  | **7** | On what basis potentially eligible participants were identified (such as symptoms, results from previous tests, inclusion in registry) |
|  |  | **8** | Where and when potentially eligible participants were identified (setting, location and dates) |
|  |  | **9** | Whether participants formed a consecutive, random or convenience series |
|  | *Test methods* | **10a** | Index test, in sufficient detail to allow replication |
|  |  | **10b** | Reference standard, in sufficient detail to allow replication |
|  |  | **11** | Rationale for choosing the reference standard (if alternatives exist) |
|  |  | **12a** | Definition of and rationale for test positivity cut-offs or result categories of the index test, distinguishing pre-specified from exploratory |
|  |  | **12b** | Definition of and rationale for test positivity cut-offs or result categories of the reference standard, distinguishing pre-specified from exploratory |
|  |  | **13a** | Whether clinical information and reference standard results were available to the performers/readers of the index test |
|  |  | **13b** | Whether clinical information and index test results were available to the assessors of the reference standard |
|  | *Analysis* | **14** | Methods for estimating or comparing measures of diagnostic accuracy |
|  |  | **15** | How indeterminate index test or reference standard results were handled |
|  |  | **16** | How missing data on the index test and reference standard were handled |
|  |  | **17** | Any analyses of variability in diagnostic accuracy, distinguishing pre-specified from exploratory |
|  |  | **18** | Intended sample size and how it was determined |
|  | **RESULTS** |  |  |
|  | *Participants* | **19** | Flow of participants, using a diagram |
|  |  | **20** | Baseline demographic and clinical characteristics of participants |
|  |  | **21a** | Distribution of severity of disease in those with the target condition |
|  |  | **21b** | Distribution of alternative diagnoses in those without the target condition |
|  |  | **22** | Time interval and any clinical interventions between index test and reference standard |
|  | *Test results* | **23** | Cross tabulation of the index test results (or their distribution) by the results of the reference standard |
|  |  | **24** | Estimates of diagnostic accuracy and their precision (such as 95% confidence intervals) |
|  |  | **25** | Any adverse events from performing the index test or the reference standard |
|  | **DISCUSSION** |  |  |
|  |  | **26** | Study limitations, including sources of potential bias, statistical uncertainty, and generalizability |
|  |  | **27** | Implications for practice, including the intended use and clinical role of the index test |
|  | **OTHER INFORMATION** |  |  |
|  |  | **28** | Registration number and name of registry |
|  |  | **29** | Where the full study protocol can be accessed |
|  |  | **30** | Sources of funding and other support; role of funders |
|  |  |  |  |

**Supplementary table 2.** Immunohistochemical expression in intestinal tissue of DPP-4/CD26.

|  |  |
| --- | --- |
|  | **UC** |
| **Clinical remission****(n=5)** | **Clinical activity****(n=8)** | ***P-value*** |
| **DPP-4 / CD26 (no IHC expression), n (%)** | 2 (40) | 8 (100) | 0.012 |
| **DPP-4 / CD26 (IHC expression), n (%)** | 3 (60) | 0 |
|  | **Ileal CD** |
| **Clinical remission****(n=5)** | **Clinical activity****(n=7)** | ***P-value*** |
| **DPP-4 / CD26 (no IHC expression), n (%)** | 0 | 2 (29) | 0.190 |
| **DPP-4 / CD26 (IHC expression), n (%)** | 5 (100) | 5 (71) |
|  | **Healthy controls** |
| **Ileum****(n=5)** | **Colon****(n=5)** | ***P-value*** |
| **DPP-4 / CD26 (no IHC expression), n (%)** | 0 | 5 (100) | 0.002 |
| **DPP-4 / CD26 (IHC expression), n (%)** | 5 (100) | 0 |

IHC - Immunohistochemical